Synektik SA
Synektik SA develops and distributes advanced medical equipment and technology solutions, primarily serving healthcare institutions and providers.
Business. Synektik SA (SNTP.WA) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
5 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Synektik SA (SNTP.WA) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Synektik maintains a strong liquidity position with a current ratio of 1.65 and cash and equivalents of 84.25 million PLN, which supports operational flexibility and short-term obligations. The company's debt-to-equity ratio of 0.18 indicates a conservative capital structure, with long-term debt at 40.23 million PLN and total equity at 222.78 million PLN. Free cash flow of 57.36 million PLN and operating cash flow of 77.73 million PLN further reinforce its liquidity profile.
The company's profitability is robust, with a return on equity of 45.87% and return on assets of 21%, both exceeding typical thresholds for the healthcare equipment industry. Operating income of 157.02 million PLN and net income of 102.19 million PLN reflect strong cost control and revenue generation. Gross profit of 242.59 million PLN on revenue of 681.29 million PLN suggests a healthy margin structure.
Synektik's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification may expose the company to regional market risks, particularly in the healthcare equipment sector.
The company's growth trajectory is supported by strong analyst sentiment, with a mean price target of 319.38 PLN and a median of 312.65 PLN. Analysts have issued three strong-buy and two buy recommendations, with no hold or negative ratings. The absence of negative analyst sentiment suggests confidence in the company's near-term performance.
Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure remains stable, with no dilution potential identified in the latest financial data. However, the healthcare equipment industry is subject to regulatory and technological changes, which could impact long-term performance.
Recent events include strong analyst coverage and positive price target estimates, with no disclosed earnings call transcripts or regulatory filings indicating material changes in the company's operations. The absence of recent negative events supports the current positive outlook.
- Synektik maintains a strong liquidity position with a current ratio of 1.65 and 84.25 million PLN in cash and equivalents.
- The company's profitability is robust, with a return on equity of 45.87% and return on assets of 21%.
- Analysts have issued three strong-buy and two buy recommendations, with no hold or negative ratings.
- The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
- Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 17,91 |
| Revenue | —no estimate | —no estimate | 918,5M PLN |
| Operating income | —no estimate | —no estimate | 209,6M PLN |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Synektik SA Market data — financials · 2026-05-29
- Synektik SA Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Artur Mieczyslaw OstrowskiMember of the Management Board
- Mariusz Wojciech KsiazekChairman of the Supervisory Board